Want to see AU:LDX full AI Analyst Report?

Lumos Diagnostics Holdings Ltd. (LDX) Price & Analysis

28 Followers

LDX Stock Chart & Stats

AU$0.32

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.32

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.33

Previous CloseN/A

Volume213.94K

Average Volume (3M)5.63M

Market Cap

AU$108.60M

Enterprise ValueAU$67.83M

Total Cash (Recent Filing)AU$3.00M

Total Debt (Recent Filing)AU$11.85M

Price to Earnings (P/E)―

Beta2.02

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding944,389,160

10 Day Avg. Volume3,659,446

30 Day Avg. Volume5,628,467

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.96

Price to Sales (P/S)0.97

P/FCF Ratio-1.29

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$36.18M

Bulls Say, Bears Say

Bulls Say

Distribution AgreementA secured 6-year exclusive distribution pact providing a USD 317M minimum creates durable revenue visibility and reduces commercialization execution risk. A committed channel partner materially de-risks U.S. market access and provides predictable demand for planning manufacturing and sales investments.

Reimbursement CoverageEstablished CMS reimbursement at a defined rate strengthens unit economics and supports sustained physician adoption in office settings. Durable payor coverage lowers pricing resistance, improves per-test margins, and makes commercial rollouts more scalable across decentralized care venues.

High Gross MarginsConsistently high product gross margins (circa 60%+) indicate a structurally profitable product mix for each incremental sale. Combined with early operating cash flow improvement, strong unit economics support long-term margin sustainability and allow reinvestment in commercial expansion without eroding per-unit profitability.

Bears Say

High LeverageMaterial leverage limits financial flexibility and raises the cost of capital for necessary capacity expansions. High debt levels strain cash available for commercial scaling, increase refinancing risk in adverse markets, and reduce ability to absorb delays in revenue ramp from new contracts.

Negative Cash Flow HistoryA history of negative operating and free cash flow indicates structural cash generation weaknesses. Even with recent improvement, persistent cash outflows force reliance on external funding or nondilutive grants, complicating long-term investment in manufacturing capacity and sustained commercial expansion.

Regulatory DependencyKey U.S. commercial ramp and the PHASE minimum revenues hinge on a CLIA waiver grant. This regulatory dependency controls market access into point-of-care CLIA‑waived settings; an adverse or delayed decision would materially compress addressable market, timing of cash flows, and partner-driven revenue realization.

Lumos Diagnostics Holdings Ltd. News

Lumos Diagnostics Secures A$709,837 R&D Tax Rebate to Advance Point-of-Care Platforms

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) just unveiled an update. Lumos Diagnostics has received a cash refund...

2d ago

LDX

Lumos Diagnostics Director Sam Lanyon Increases Shareholding via On‑Market Purchase

An announcement from Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) is now available. Lumos Diagnostics has disclosed a...

5d ago

LDX

Lumos Diagnostics Seeks ASX Quotation for 15.2 Million New Shares

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) has issued an update. Lumos Diagnostics Holdings Limited has applied to...

8d ago

LDX

Lumos Diagnostics Director Catherine Robson Increases Indirect Shareholding

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) has provided an update. Lumos Diagnostics Holdings Ltd. disclosed a change...

12d ago

LDX

Lumos Diagnostics Updates Director Doug Ward’s Expanded Equity Holding

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) has provided an update. Lumos Diagnostics Holdings Ltd. has disclosed a...

25d ago

LDX

Lumos ramps up U.S. rollout of FebriDx ahead of investor briefing

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) has issued an announcement. Lumos Diagnostics is expanding the U.S. rollout...

27d ago

LDX

Lumos Secures BARDA Milestone as FebriDx CLIA Waiver Unlocks US$1bn Market

An announcement from Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) is now available. Lumos Diagnostics has received a...

2M ago

LDX

Lumos Director Catherine Robson Increases Indirect Shareholding via Purchases and Share Plan

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) has shared an update. Lumos Diagnostics Holdings Ltd. has disclosed a...

2M ago

LDX

Lumos Director Increases Stake via Share Purchase Plan

Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ) has shared an announcement. Lumos Diagnostics director Sam Lanyon has increased...

2M ago

LDX

Lumos Diagnostics Issues 44.4 Million Unlisted Options

The latest announcement is out from Lumos Diagnostics Holdings Ltd. ( ($AU:LDX) ). Lumos Diagnostics Holdings Ltd. has...

2M ago

LDX

LDX FAQ

What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?

Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.03 and its highest was AU$0.33 in the past 12 months.

What is Lumos Diagnostics Holdings Ltd.’s market cap?

Lumos Diagnostics Holdings Ltd.’s market cap is AU$108.60M.

When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?

Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 63 days.

How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?

Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.

Is Lumos Diagnostics Holdings Ltd. overvalued?

According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lumos Diagnostics Holdings Ltd. pay dividends?

Lumos Diagnostics Holdings Ltd. does not currently pay dividends.

What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?

Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?

Lumos Diagnostics Holdings Ltd. has 944,389,160 shares outstanding.

What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?

Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.

Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?

Currently, no hedge funds are holding shares in AU:LDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Lumos Diagnostics Holdings Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-164.12%

Trailing 12-Months

Asset Growth

-26.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.